Rifabutinum [Latin] en es it fr

Rifabutinum [Latin] Brand names, Rifabutinum [Latin] Analogs

Rifabutinum [Latin] Brand Names Mixture

  • No information avaliable

Rifabutinum [Latin] Chemical_Formula


Rifabutinum [Latin] RX_link


Rifabutinum [Latin] fda sheet

Rifabutinum_[Latin] FDA

Rifabutinum [Latin] msds (material safety sheet)

Rifabutinum_[Latin] MSDS

Rifabutinum [Latin] Synthesis Reference

No information avaliable

Rifabutinum [Latin] Molecular Weight

847.005 g/mol

Rifabutinum [Latin] Melting Point

No information avaliable

Rifabutinum [Latin] H2O Solubility

Minimally soluble (0.19 mg/mL)

Rifabutinum [Latin] State


Rifabutinum [Latin] LogP


Rifabutinum [Latin] Dosage Forms


Rifabutinum [Latin] Indication

For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Rifabutinum [Latin] Pharmacology

Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifabutin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.

Rifabutinum [Latin] Absorption

Rifabutin is readily absorbed from the gastrointestinal tract, with an absolute bioavailability averaging 20%.

Rifabutinum [Latin] side effects and Toxicity

LD50 = 4.8 g/kg (mouse, male)

Rifabutinum [Latin] Patient Information

Patients should be advised of the signs and symptoms of both MAC and tuberculosis, and should be instructed to consult their physicians if they develop new complaints consistent with either of these diseases. In addition, since MYCOBUTIN may rarely be associated with myositis and uveitis, patients should be advised to notify their physicians if they develop signs or symptoms suggesting either of these disorders.

Urine, feces, saliva, sputum, perspiration, tears, and skin may be colored brown-orange with rifabutin and some of its metabolites. Soft contact lenses may be permanently stained. Patients to be treated with MYCOBUTIN should be made aware of these possibilities.

Rifabutinum [Latin] Organisms Affected

Enteric bacteria and other eubacteria